

# Manuel Rubio-Rivas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6963973/publications.pdf>

Version: 2024-02-01

65  
papers

1,642  
citations

393982

19  
h-index

329751

37  
g-index

75  
all docs

75  
docs citations

75  
times ranked

2470  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-“Polymyositis/Scl Antibodies in Systemic Sclerosis. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e180-e188.	0.5	6
2	Coronavirus disease 2019 hospitalization outcomes in persons with and without HIV in Spain. <i>Aids</i> , 2022, 36, 683-690.	1.0	4
3	Clinical Features and Risk Factors for Mortality Among Long-term Care Facility Residents Hospitalized Due to COVID-19 in Spain. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, e138-e147.	1.7	7
4	Influencia de la historia de tabaquismo en la evoluci3n de la hospitalizaci3n en pacientes COVID-19 positivos: datos del registro SEMI-COVID-19. <i>Medicina Clnica</i> , 2022, 159, 214-223.	0.3	7
5	Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19. <i>PLoS ONE</i> , 2022, 17, e0261711.	1.1	1
6	Influence of chronic use of corticosteroids and calcineurin inhibitors on COVID-19 clinical outcomes: analysis of a nationwide registry. <i>International Journal of Infectious Diseases</i> , 2022, 116, 51-58.	1.5	17
7	Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension. <i>Scientific Reports</i> , 2022, 12, 5289.	1.6	6
8	Clusters of inflammation in COVID-19: descriptive analysis and prognosis on more than 15,000 patients from the Spanish SEMI-COVID-19 Registry. <i>Internal and Emergency Medicine</i> , 2022, 17, 1115-1127.	1.0	4
9	Factores de riesgo de mortalidad en pacientes con infecci3n por SARS-CoV-2 y fibrilaci3n auricular: datos del registro SEMI-COVID-19. <i>Medicina Clnica</i> , 2022, 159, 457-464.	0.3	4
10	Ethnicity and Clinical Outcomes in Patients Hospitalized for COVID-19 in Spain: Results from the Multicenter SEMI-COVID-19 Registry. <i>Journal of Clinical Medicine</i> , 2022, 11, 1949.	1.0	4
11	WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales. <i>Journal of General Internal Medicine</i> , 2022, 37, 1980-1987.	1.3	27
12	C-Reactive Protein and Serum Albumin Ratio: A Feasible Prognostic Marker in Hospitalized Patients with COVID-19. <i>Biomedicines</i> , 2022, 10, 1393.	1.4	6
13	Remdesivir in Very Old Patients (80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry. <i>Journal of Clinical Medicine</i> , 2022, 11, 3769.	1.0	10
14	The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: Systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2021, 20, 102713.	2.5	23
15	The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i). <i>Rheumatology</i> , 2021, 60, 872-880.	0.9	4
16	Gender-Based Differences by Age Range in Patients Hospitalized with COVID-19: A Spanish Observational Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 899.	1.0	10
17	Impact of Arterial Stiffness on All-Cause Mortality in Patients Hospitalized With COVID-19 in Spain. <i>Hypertension</i> , 2021, 77, 856-867.	1.3	44
18	Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry. <i>Journal of Clinical Medicine</i> , 2021, 10, 1844.	1.0	12

#	ARTICLE	IF	CITATIONS
19	Risk Categories in COVID-19 Based on Degrees of Inflammation: Data on More Than 17,000 Patients from the Spanish SEMI-COVID-19 Registry. <i>Journal of Clinical Medicine</i> , 2021, 10, 2214.	1.0	15
20	Inappropriate antibiotic use in the COVID-19 era: Factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID. <i>PLoS ONE</i> , 2021, 16, e0251340.	1.1	72
21	Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 2642.	1.0	9
22	Prone Position in COVID-19 Patients With Severe Acute Respiratory Distress Syndrome Receiving Conventional Oxygen Therapy: A Retrospective Study. <i>Archivos De Bronconeumologia</i> , 2021, 58, 277-277.	0.4	5
23	Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study. <i>Journal of Infection</i> , 2021, 82, 276-316.	1.7	7
24	Predicting critical illness on initial diagnosis of COVID-19 based on easily obtained clinical variables: development and validation of the PRIORITY model. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1838-1844.	2.8	16
25	Estimation of Admission D-dimer Cut-off Value to Predict Venous Thrombotic Events in Hospitalized COVID-19 Patients: Analysis of the SEMI-COVID-19 Registry. <i>Journal of General Internal Medicine</i> , 2021, 36, 3478-3486.	1.3	16
26	Frequency, risk factors, and outcomes of hospital readmissions of COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 13733.	1.6	27
27	Clinical Characteristics and Risk Factors of Respiratory Failure in a Cohort of Young Patients Requiring Hospital Admission with SARS-CoV2 Infection in Spain: Results of the Multicenter SEMI-COVID-19 Registry. <i>Journal of General Internal Medicine</i> , 2021, 36, 3080-3087.	1.3	7
28	High-Dose Methylprednisolone Pulses for 3 Days vs. Low-Dose Dexamethasone for 10 Days in Severe, Non-Critical COVID-19: A Retrospective Propensity Score Matched Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4465.	1.0	7
29	Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis. <i>Pharmacotherapy</i> , 2021, 41, 884-906.	1.2	27
30	The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers. <i>Journal of General Internal Medicine</i> , 2021, , 1.	1.3	7
31	Real-Life Impact of Glucocorticoid Treatment in COVID-19 Mortality: A Multicenter Retrospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4678.	1.0	3
32	Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry. <i>Journal of Clinical Medicine</i> , 2021, 10, 4610.	1.0	4
33	Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy. <i>BMC Infectious Diseases</i> , 2021, 21, 1144.	1.3	45
34	Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry. <i>Internal and Emergency Medicine</i> , 2021, , 1.	1.0	6
35	Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study. <i>Journal of Rheumatology</i> , 2020, 47, 89-98.	1.0	11
36	Sarcoidosis presenting with and without Löfgren's syndrome: Clinical, radiological and behavioral differences observed in a group of 691 patients. <i>Joint Bone Spine</i> , 2020, 87, 141-147.	0.8	23

#	ARTICLE	IF	CITATIONS
37	Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness. <i>International Journal of Infectious Diseases</i> , 2020, 101, 290-297.	1.5	33
38	Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study. <i>BMC Medicine</i> , 2020, 18, 359.	2.3	81
39	Predicting Clinical Outcome with Phenotypic Clusters in COVID-19 Pneumonia: An Analysis of 12,066 Hospitalized Patients from the Spanish Registry SEMI-COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 3488.	1.0	59
40	Clinical features and outcomes of asymptomatic pulmonary sarcoidosis. A comparative cohort study. <i>Respiratory Medicine</i> , 2020, 169, 105998.	1.3	7
41	Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in melanoma. <i>Autoimmunity Reviews</i> , 2020, 19, 102587.	2.5	20
42	Comment to: Cluster analysis for clinical sarcoidosis' phenotyping. <i>European Journal of Internal Medicine</i> , 2020, 78, 142.	1.0	0
43	Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation. <i>Autoimmunity Reviews</i> , 2020, 19, 102507.	2.5	13
44	The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. <i>Lancet Rheumatology</i> , The, 2020, 2, e71-e83.	2.2	182
45	Clinical phenotypes and prediction of chronicity in sarcoidosis using cluster analysis in a prospective cohort of 694 patients. <i>European Journal of Internal Medicine</i> , 2020, 77, 59-65.	1.0	18
46	LAUDES Study: impact of digital ulcers on hand functional limitation, work productivity and daily activities, in systemic sclerosis patients. <i>Rheumatology International</i> , 2019, 39, 1875-1882.	1.5	8
47	Elderly sarcoidosis: A comparative study from a 42-year single-centre experience. <i>Respiratory Medicine</i> , 2019, 152, 1-6.	1.3	12
48	Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry. <i>Clinical Rheumatology</i> , 2019, 38, 1117-1124.	1.0	7
49	Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. <i>Rheumatology International</i> , 2018, 38, 363-374.	1.5	48
50	Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 849-857.	1.6	16
51	First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study. <i>Clinical Rheumatology</i> , 2018, 37, 999-1009.	1.0	27
52	Recurrence of Lofgren's syndrome 32 years later. A case report and review of the literature. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2018, 35, 289-291.	0.2	0
53	Occupational and environmental scleroderma. Systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2017, 36, 569-582.	1.0	81
54	Analysis of <i>ATP8B4</i> F436L Missense Variant in a Large Systemic Sclerosis Cohort. <i>Arthritis and Rheumatology</i> , 2017, 69, 1337-1338.	2.9	9

#	ARTICLE	IF	CITATIONS
55	Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort. <i>Autoimmunity Reviews</i> , 2017, 16, 796-802.	2.5	16
56	Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis. <i>Medicine (United States)</i> , 2017, 96, e7595.	0.4	82
57	Changes in the pattern of death of 987 patients with systemic sclerosis from 1990 to 2009 from the nationwide Spanish Scleroderma Registry (RESCLE). <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 40-47.	0.4	6
58	Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 98-105.	0.4	8
59	Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 200-208.	1.6	34
60	Lymphopenia as prognostic factor for mortality and hospital length of stay for elderly hospitalized patients. <i>Aging Clinical and Experimental Research</i> , 2016, 28, 721-727.	1.4	19
61	Applying the ACR/EULAR Systemic Sclerosis Classification Criteria to the Spanish Scleroderma Registry Cohort. <i>Journal of Rheumatology</i> , 2015, 42, 2327-2331.	1.0	13
62	Mortality and survival in systemic sclerosis: Systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 208-219.	1.6	261
63	Systemic mastocytosis presenting as kounis syndrome. <i>Annals of Allergy, Asthma and Immunology</i> , 2013, 111, 570-571.	0.5	4
64	Predictors of long-term survival in nonagenarians: the NonaSantfeliu study. <i>Age and Ageing</i> , 2011, 40, 111-116.	0.7	39
65	Survival, Mortality, Causes of Death and Risk Factors of Poor Outcome. , 0, , .		2